These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 32001173

  • 1. Protective activity of anti-lipoteichoic acid monoclonal antibody in single or combination therapies in methicillin-resistant Staphylococcus aureus-induced murine sepsis models.
    Ohsawa H, Baba T, Enami J, Hiramatsu K.
    J Infect Chemother; 2020 May; 26(5):520-522. PubMed ID: 32001173
    [Abstract] [Full Text] [Related]

  • 2. Successful selection of an infection-protective anti-Staphylococcus aureus monoclonal antibody and its protective activity in murine infection models.
    Ohsawa H, Baba T, Enami J, Hiramatsu K.
    Microbiol Immunol; 2015 Apr; 59(4):183-92. PubMed ID: 25659598
    [Abstract] [Full Text] [Related]

  • 3. Monoclonal Antibody Targeting Staphylococcus aureus Surface Protein A (SasA) Protect Against Staphylococcus aureus Sepsis and Peritonitis in Mice.
    Yang Y, Qian M, Yi S, Liu S, Li B, Yu R, Guo Q, Zhang X, Yu C, Li J, Xu J, Chen W.
    PLoS One; 2016 Apr; 11(2):e0149460. PubMed ID: 26926145
    [Abstract] [Full Text] [Related]

  • 4. Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models.
    Smith JR, Barber KE, Hallesy J, Raut A, Rybak MJ.
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5529-34. PubMed ID: 26124162
    [Abstract] [Full Text] [Related]

  • 5. Clinical implications of vancomycin heteroresistant and intermediately susceptible Staphylococcus aureus.
    Gomes DM, Ward KE, LaPlante KL.
    Pharmacotherapy; 2015 Apr; 35(4):424-32. PubMed ID: 25884530
    [Abstract] [Full Text] [Related]

  • 6. Analysis of synergy between beta-lactams and anti-methicillin-resistant Staphylococcus aureus agents from the standpoint of strain characteristics and binding action.
    Ono D, Yamaguchi T, Hamada M, Sonoda S, Sato A, Aoki K, Kajiwara C, Kimura S, Fujisaki M, Tojo H, Sasaki M, Murakami H, Kato K, Ishii Y, Tateda K.
    J Infect Chemother; 2019 Apr; 25(4):273-280. PubMed ID: 30713034
    [Abstract] [Full Text] [Related]

  • 7. Monoclonal antibody anti-PBP2a protects mice against MRSA (methicillin-resistant Staphylococcus aureus) infections.
    Saraiva FB, de Araújo ACC, de Araújo AÉV, Senna JPM.
    PLoS One; 2019 Apr; 14(11):e0225752. PubMed ID: 31774881
    [Abstract] [Full Text] [Related]

  • 8. Comparison of linezolid step-down therapy to standard parenteral therapy in methicillin-resistant Staphylococcus aureus bloodstream infections.
    Yeager SD, Oliver JE, Shorman MA, Wright LR, Veve MP.
    Int J Antimicrob Agents; 2021 May; 57(5):106329. PubMed ID: 33785363
    [Abstract] [Full Text] [Related]

  • 9. In vitro ceftaroline combinations against meticillin-resistant Staphylococcus aureus.
    García AB, Candel FJ, López L, Chiarella F, Viñuela-Prieto JM.
    J Med Microbiol; 2016 Oct; 65(10):1119-1122. PubMed ID: 27553740
    [Abstract] [Full Text] [Related]

  • 10. Future trends in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection: An in-depth review of newer antibiotics active against an enduring pathogen.
    Bal AM, David MZ, Garau J, Gottlieb T, Mazzei T, Scaglione F, Tattevin P, Gould IM.
    J Glob Antimicrob Resist; 2017 Sep; 10():295-303. PubMed ID: 28732783
    [Abstract] [Full Text] [Related]

  • 11. Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 μg/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents.
    Campbell ML, Marchaim D, Pogue JM, Sunkara B, Bheemreddy S, Bathina P, Pulluru H, Chugh N, Wilson MN, Moshos J, Ku K, Hayakawa K, Martin ET, Lephart PR, Rybak MJ, Kaye KS.
    Ann Pharmacother; 2012 Dec; 46(12):1587-97. PubMed ID: 23212935
    [Abstract] [Full Text] [Related]

  • 12. Differential effects of antibiotics on neutrophils exposed to lipoteichoic acid derived from Staphylococcus aureus.
    Algorri M, Wong-Beringer A.
    Ann Clin Microbiol Antimicrob; 2020 Nov 03; 19(1):50. PubMed ID: 33143710
    [Abstract] [Full Text] [Related]

  • 13. Monoclonal antibodies protect from Staphylococcal Enterotoxin K (SEK) induced toxic shock and sepsis by USA300 Staphylococcus aureus.
    Aguilar JL, Varshney AK, Pechuan X, Dutta K, Nosanchuk JD, Fries BC.
    Virulence; 2017 Aug 18; 8(6):741-750. PubMed ID: 27715466
    [Abstract] [Full Text] [Related]

  • 14. Observed Antagonistic Effect of Linezolid on Daptomycin or Vancomycin Activity against Biofilm-Forming Methicillin-Resistant Staphylococcus aureus in an In Vitro Pharmacodynamic Model.
    Luther MK, LaPlante KL.
    Antimicrob Agents Chemother; 2015 Dec 18; 59(12):7790-4. PubMed ID: 26369963
    [Abstract] [Full Text] [Related]

  • 15. Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan.
    Huang YT, Hsiao CH, Liao CH, Lee CW, Hsueh PR.
    J Clin Microbiol; 2008 Mar 18; 46(3):1132-6. PubMed ID: 18199793
    [Abstract] [Full Text] [Related]

  • 16. [A multicentric study on clinical characteristics and antibiotic sensitivity in children with methicillin-resistant Staphylococcus aureus infection].
    Wu X, Yu H, He LY, Wang CQ, Xu HM, Zhao RQ, Jing CM, Chen YH, Chen J, Deng JK, Shi J, Lin AW, Li L, Deng HL, Cai HJ, Chen YP, Wen ZW, Yang JH, Zhang T, Xiao FF, Cao Q, Huang WC, Hao JH, Zhang CH, Huang YY, Ji XF.
    Zhonghua Er Ke Za Zhi; 2020 Aug 02; 58(8):628-634. PubMed ID: 32842382
    [Abstract] [Full Text] [Related]

  • 17. Activity of Different Antistaphylococcal Therapies, Alone or Combined, in a Rat Model of Methicillin-Resistant Staphylococcus epidermidis Osteitis without Implant.
    Albac S, Labrousse D, Hayez D, Anzala N, Bonnot D, Chavanet P, Aslangul E, Croisier D.
    Antimicrob Agents Chemother; 2020 Jan 27; 64(2):. PubMed ID: 31740562
    [Abstract] [Full Text] [Related]

  • 18. In vivo development of daptomycin resistance in vancomycin-susceptible methicillin-resistant Staphylococcus aureus severe infections previously treated with glycopeptides.
    Capone A, Cafiso V, Campanile F, Parisi G, Mariani B, Petrosillo N, Stefani S.
    Eur J Clin Microbiol Infect Dis; 2016 Apr 27; 35(4):625-31. PubMed ID: 26815434
    [Abstract] [Full Text] [Related]

  • 19. Australian Group on Antimicrobial Resistance (AGAR) Australian Staphylococcus aureus Sepsis Outcome Programme (ASSOP) Annual Report 2018.
    Coombs GW, Daley DA, Mowlaboccus S, Lee YT, Pang S, Australian Group on Antimicrobial Resistance.
    Commun Dis Intell (2018); 2020 Mar 16; 44():. PubMed ID: 32178604
    [Abstract] [Full Text] [Related]

  • 20. A Human Biofilm-Disrupting Monoclonal Antibody Potentiates Antibiotic Efficacy in Rodent Models of both Staphylococcus aureus and Acinetobacter baumannii Infections.
    Xiong YQ, Estellés A, Li L, Abdelhady W, Gonzales R, Bayer AS, Tenorio E, Leighton A, Ryser S, Kauvar LM.
    Antimicrob Agents Chemother; 2017 Oct 16; 61(10):. PubMed ID: 28717038
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.